6533b853fe1ef96bd12ad6ee

RESEARCH PRODUCT

Long-Term Outcome with New Generation Prostheses in Patients Undergoing Transcatheter Aortic Valve Replacement

Ralph Stephan Von BardelebenMartin GeyerAlexander R TammEberhard SchulzThomas MünzelFelix KreidelCaroline JablonskiLea DausmannOmar Hahad

subject

medicine.medical_specialtymedicine.medical_treatmentaortic valve stenosis030204 cardiovascular system & hematologyTAVRnew-generation trans-catheter heart valvesProsthesisArticle03 medical and health sciences0302 clinical medicineValve replacementInternal medicinemedicine030212 general & internal medicineMyocardial infarctionStrokeEjection fractionbusiness.industryRGeneral Medicinemedicine.diseaseStenosisAortic valve stenosisCardiologyMedicineImplantbusinesslong-term outcomes

description

The aim of this study was to compare patients with transcatheter aortic valve replacement (TAVR) receiving new generation prostheses SAPIEN 3 (S3, Edwards Lifesc.) and Evolut R (ER, Medtronic Inc.) in terms of periprocedural and long-term outcome. Our retrospective, single-center analysis included 359 consecutive patients with severe aortic stenosis who underwent TAVR with S3 or ER from 2014–2016 (mean age 82 ± 7 years, 47% male, mean EuroSCORE II 8.0 ± 8%, mean follow-up 3.8 years). Device Success was equal (S3 93.0% vs. ER 92.4%, p = 0.812). We report a 30-day mortality of 2.8% in the S3 group, and 2.1% in the ER group (p = 0.674). There was no difference in stroke, conversion to open surgery, vascular and bleeding complications or myocardial infarction. While prosthesis mean gradients were higher with S3 (12.0 mmHg vs. 8.2 mmHg, p &lt

yearjournalcountryeditionlanguage
2021-07-01Journal of Clinical Medicine
10.3390/jcm10143102http://europepmc.org/articles/PMC8303957